Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15744225 | 1.00 | KMT2A (0.48) | KMT2APTGS2PTGS1CYP1A2CYP2D6 | |
| SCHEMBL8029603 | 1.00 | KMT2A (0.48) | KMT2APTGS2PTGS1CYP1A2CYP2D6 | |
| SCHEMBL5692490 | 0.83 | KMT2A (0.52) | KMT2APTGS2PTGS1CYP2D6FAAH | |
| SCHEMBL7651108 | 0.83 | KMT2A (0.52) | KMT2APTGS2PTGS1CYP2D6FAAH | |
| SCHEMBL6922515 | 0.82 | PTGS1 (0.72) | KMT2APTGS2PTGS1CYP2D6ALOX5 | |
| SCHEMBL28393668 | 0.82 | ESR1 (0.46) | KMT2APTGS1CYP1A2CYP2D6SMN1; SMN2 | |
| SCHEMBL28308787 | 0.82 | ESR1 (0.46) | KMT2APTGS1CYP1A2CYP2D6SMN1; SMN2 | |
| SCHEMBL1000872 | 0.82 | LMNA (0.40) | PTGS2CYP1A2LMNAKDM4EL3MBTL1 | |
| SCHEMBL183940 | 0.81 | KMT2A (0.67) | KMT2APTGS2PTGS1LMNAL3MBTL1 | |
| SCHEMBL5544986 | 0.81 | KMT2A (0.67) | KMT2APTGS2PTGS1LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040171543-A1 | Matrix metalloproteinase inhibitors and methods for identification of lead compounds | WARNER-LAMBERT COMPANY LLC | 2004-09-02 | — | — | US | disclosed |
| WO-2004014381-A2 | MATRIX METALLOPROTEINASE INHIBITORS AND METHODS FOR IDENTIFICATION OF LEAD COMPOUNDS | WARNER-LAMBERT COMPANY LLC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171543-A1 | Matrix metalloproteinase inhibitors and methods for identification of lead compounds | MMP13, MMP3, MMP26 | KMT2A 2659/4885PTGS2 671/4885PTGS1 414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.